IsoPlexis — Merger or Acquisition (February 2023)
6 slides from IsoPlexis's merger presentation, Feb 7, 2023
Slide 1: BLI Leadership Team With Deep Life Science Experience
BLI Leadership Team With Deep Life Science Experience Winning culture a = = eee Siddhartha Kadia, Ph.D. Mehul Joshi Customer Centricity Chief Executive Officer Chief Financial Officer Chief Business Officer eo } Continuing Innovation eee j Commitment to a eee Rolando Brawer, Ph.0. Excellence in Qual
Slide 2: Integration Planning for PhenomeX
INTEGRATION PLANNING FOR PhenomexX A PREMIER FUNCTIONAL CELL BIOLOGY ‘COMPANY
Slide 3: Three- to five-year strategic operating plan
Three- to five-year strategic operating plan IGi Generate positive operating cash flow Deliver consistent commercial execution Prioritize R&D return on investment Build a world- class team with a proven track record in profitably scaling life sciences tools and services companies through increased f
Slide 4: Timeline
Timeline , We are here. PhenomexX Deal Signing Z Day 1 Financials SEC Review Shareholder Vote ‘Company Confidential, For internal Use Only.
Slide 5: The blueprint for PhenomeX
The blueprint for PhenomeX Create a Premier Functional Cell Biology Company © Building a world-class team with focus on PhenomeX commercial channel * Innovation engine to create the best product pipeline * Path to ~$300M in revenue by 2027 A Growing, Profitable, & Sustainable Company * Cashflow posi
Slide 6: Forward-Looking Statements
Forward-Looking Statements Certain statements in this communication regarding the proposed transaction between Berkeley Lights and IsoPlexis, the expected timetable for completing the transaction, benefits and synergies of the transaction, future opportunities for the combined company and products a